Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PRKDC | P78527 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320671 | 1.00 | MAPT (0.68) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL16052466 | 0.94 | MAPT (0.60) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL4891360 | 0.94 | MAPT (0.55) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL21352658 | 0.93 | ALDH1A1 (0.68) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL1609308 | 0.90 | ALDH1A1 (0.52) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL15984634 | 0.88 | MAPT (0.54) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL9738690 | 0.87 | MAPT (0.49) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL15952707 | 0.87 | MAPT (0.53) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL187778 | 0.87 | MAPT (0.53) | MAPTALDH1A1KDM4ECYP3A4ALOX15 | |
| SCHEMBL187779 | 0.87 | MAPT (0.53) | MAPTALDH1A1KDM4ECYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025149667-A1 | ANTIBODY DRUG CONJUGATES AND USES THEREOF | PHEON THERAPEUTICS LTD (GB) | 2025-07-17 | — | — | WO | disclosed |
| EP-4554624-A1 | ANTIBODY-DRUG CONJUGATES | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | disclosed |
| EP-4554623-A1 | ANTIBODY DRUG CONJUGATES THAT BIND CDCP1 AND USES THEREOF | Pheon Therapeutics Ltd (GB) | 2025-05-21 | — | — | EP | disclosed |
| CN-119859101-A | Antibacterial and anti-inflammatory drug controllable release hydrogel and preparation method and application thereof | 西北工业大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| EP-1144373-A3 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1149069-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| EP-1144373-A2 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000041531-A2 | SERINE PROTEASE INHIBITORS | GENENTECH, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000035858-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | MAPT 3224/4885ALDH1A1 1463/4885KDM4E 1922/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | MAPT 4580/4885ALDH1A1 3182/4885KDM4E 1454/4885 |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | MAPT 1417/4885ALDH1A1 2850/4885KDM4E 1998/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | MAPT 24/4885ALDH1A1 1177/4885KDM4E 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.